Literature DB >> 2981431

Bovine leukemia virus long terminal repeat: a cell type-specific promoter.

D Derse, S J Caradonna, J W Casey.   

Abstract

The functional activity of the promoter unit contained within the long terminal repeat (LTR) of bovine leukemia virus (BLV) was examined by monitoring transient expression of a heterologous gene placed under its control. Various cell lines were transfected with recombinant plasmids carrying the bacterial chloramphenicol acetyltransferase (CAT) gene coupled to the BLV LTR (pBL-cat). Transient expression of CAT activity directed by the BLV LTR was observed only in the established BLV-producer cell lines derived from fetal lamb kidney (FLK) cells and bat lung cells. The amount of CAT activity transiently expressed in FLK-BLV cells was decreased approximately tenfold by deletion of LTR sequences located within a region 100 to 170 nucleotides upstream of the RNA start site. Surprisingly, removal of the region 50 base pairs downstream of the RNA initiation site to the 3'-end of the LTR reduced the expression of CAT activity by 87 percent. The BLV LTR thus appears to be an unusual promoter unit, functioning in a cell type-specific manner and possessing sequences on both the 5' and 3' sides of the RNA start site that influence gene expression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981431     DOI: 10.1126/science.2981431

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  33 in total

1.  Suboptimal enhancer sequences are required for efficient bovine leukemia virus propagation in vivo: implications for viral latency.

Authors:  C Merezak; C Pierreux; E Adam; F Lemaigre; G G Rousseau; C Calomme; C Van Lint; D Christophe; P Kerkhofs; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Localization of sequences responsible for trans-activation of the equine infectious anemia virus long terminal repeat.

Authors:  L Sherman; A Gazit; A Yaniv; T Kawakami; J E Dahlberg; S R Tronick
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

3.  In vitro methylation inhibits the promotor activity of a cloned intracisternal A-particle LTR.

Authors:  A Feenstra; J Fewell; K Lueders; E Kuff
Journal:  Nucleic Acids Res       Date:  1986-05-27       Impact factor: 16.971

4.  Transcriptional activation encoded by the v-fos gene.

Authors:  C Setoyama; R Frunzio; G Liau; M Mudryj; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

5.  Preferential transcription of HTLV-I LTR in cell-free extracts of human T cells producing HTLV-I viral proteins.

Authors:  N Matsunami; H Siomi; M Hatanaka; Y Yaoita; T Honjo
Journal:  Nucleic Acids Res       Date:  1986-06-25       Impact factor: 16.971

6.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

Authors:  B M Peterlin; P A Luciw; P J Barr; M D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses.

Authors:  M A Gonda; M J Braun; J E Clements; J M Pyper; F Wong-Staal; R C Gallo; R V Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Defibrinated bovine plasma inhibits retroviral transcription by blocking p52 activation of the NFkappaB element in the long terminal repeat.

Authors:  Marianne J van den Heuvel; Karen F Copeland; Elizabeth C Cates; Barbara J Jefferson; Robert M Jacobs
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

9.  David D. Derse, 1949-2009.

Authors:  Maureen Shuh
Journal:  Retrovirology       Date:  2009-12-01       Impact factor: 4.602

10.  An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression.

Authors:  V Kiermer; C Van Lint; D Briclet; C Vanhulle; R Kettmann; E Verdin; A Burny; L Droogmans
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.